Quantum Genomics Sa Stock Fundamentals
| ALQGC Stock | EUR 0.07 0 1.77% |
Quantum Genomics SA fundamentals help investors to digest information that contributes to Quantum Genomics' financial success or failures. It also enables traders to predict the movement of Quantum Stock. The fundamental analysis module provides a way to measure Quantum Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Quantum Genomics stock.
Quantum |
Quantum Genomics SA Company Shares Outstanding Analysis
Quantum Genomics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Quantum Genomics Shares Outstanding | 34.53 M |
Most of Quantum Genomics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Quantum Genomics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Quantum Genomics SA has 34.53 M of shares currently outstending. This is 80.87% lower than that of the Biotechnology sector and 67.69% lower than that of the Health Care industry. The shares outstanding for all France stocks is 93.96% higher than that of the company.
Quantum Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Quantum Genomics's current stock value. Our valuation model uses many indicators to compare Quantum Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quantum Genomics competition to find correlations between indicators driving Quantum Genomics's intrinsic value. More Info.Quantum Genomics SA is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quantum Genomics' earnings, one of the primary drivers of an investment's value.Quantum Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Quantum Genomics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Quantum Genomics could also be used in its relative valuation, which is a method of valuing Quantum Genomics by comparing valuation metrics of similar companies.Quantum Genomics is currently under evaluation in shares outstanding category among its peers.
Quantum Fundamentals
| Return On Equity | -1.23 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (5.48) % | |||
| Current Valuation | (11.33 M) | |||
| Shares Outstanding | 34.53 M | |||
| Shares Owned By Insiders | 9.18 % | |||
| Shares Owned By Institutions | 3.69 % | |||
| Price To Earning | (5.10) X | |||
| Price To Book | 0.32 X | |||
| Price To Sales | 1.07 X | |||
| Revenue | 116.21 K | |||
| Gross Profit | (12.47 M) | |||
| EBITDA | (18.94 M) | |||
| Net Income | (17.36 M) | |||
| Cash And Equivalents | 5.01 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 283.69 K | |||
| Current Ratio | 3.36 X | |||
| Book Value Per Share | 0.44 X | |||
| Cash Flow From Operations | (17.02 M) | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 8.8 | |||
| Beta | 0.27 | |||
| Market Capitalization | 5.65 M | |||
| Total Asset | 22.59 M | |||
| Z Score | 11.4 | |||
| Net Asset | 22.59 M |
About Quantum Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Quantum Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quantum Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quantum Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.